Nutriband Inc. Achieves Significant Revenue Growth and Advances in Abuse-Deterrent Opioid Patch Development

June 12th, 2025 2:35 PM
By: Newsworthy Staff

Nutriband Inc. reports a 63% year-over-year revenue increase in Q1 2025, alongside progress in developing AVERSA Fentanyl, potentially the first abuse-deterrent opioid patch, marking a pivotal step in safer transdermal therapies.

Nutriband Inc. Achieves Significant Revenue Growth and Advances in Abuse-Deterrent Opioid Patch Development

Nutriband Inc. (NASDAQ: NTRB) has announced a remarkable 63% year-over-year revenue increase in its Q1 2025 financial report, showcasing the company's growing financial health and operational success. This growth is primarily attributed to the expansion of its kinesiology tape manufacturing through its subsidiary, Pocono Pharma. The financial upturn is a testament to Nutriband's strategic initiatives and its ability to capitalize on market opportunities.

Beyond its financial achievements, Nutriband is making significant strides in the pharmaceutical sector with its AVERSA(TM) Fentanyl development. This innovative product is poised to become the world's first abuse-deterrent opioid patch, addressing a critical need in the fight against opioid abuse. The development of AVERSA(TM) Fentanyl represents a groundbreaking advancement in transdermal drug delivery, offering a safer alternative to traditional opioid patches that are susceptible to misuse.

The implications of Nutriband's progress are far-reaching. The potential introduction of an abuse-deterrent opioid patch could significantly impact the opioid crisis by reducing the availability of easily misused medications. For the healthcare industry, this development underscores the importance of innovation in drug delivery systems to enhance patient safety and combat drug abuse. Nutriband's achievements not only highlight its role as a leader in transdermal therapy but also its contribution to public health and safety.

As Nutriband continues to advance its AVERSA platforms, including its fentanyl patch and buprenorphine candidates, the company is reinforcing its position at the forefront of abuse-deterrent drug delivery. With recent capital funding, strategic partnerships, and an expanded intellectual property portfolio, Nutriband is well-positioned to lead the development of safer therapeutic options, marking a significant milestone in the pharmaceutical industry.

Source Statement

This news article relied primarily on a press release disributed by InvestorBrandNetwork (IBN). You can read the source press release here,

blockchain registration record for the source press release.
;